drugset / Trial / NCT05426811
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
Phase 1/2
Unknown
50 enrolled
China Medical University, China
Anshan Tumor Hospital · collabBenxi Cental Hospital · collabThe First Affiliated Hospital of Dalian Medical University · collabThe People's Hospital of Liaoning Province · collabThe Second Affiliated Hospital of Dalian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2025-07-01
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raltitrexed | Small molecule | 3 mg/m2 | Intravenous |
| Subject | Regorafenib | Small molecule | 120 mg | Oral |